Tubulis – Pushing the Boundaries of ADCs
Time: 4:30 pm
day: Day Two PM
Details:
- Advancing multiple ADC programs into the clinic, based on its novel Tubutecan linker-payload system to enable optimized, sustained on-tumor Topo-1 payload delivery
- In discovery, developing a novel linker component (Alco5) to broadly unlock novel ADC payload strategies
- Specifically and based on the platform versatility, systematically exploring degrader-based payloads to broaden the scope of intracellular payload targets